Barclays
SMMT icon

Barclays’s Summit Therapeutics SMMT Stock Holding History

Barclays’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
210,207
+161,104
+328% +$2.86M ﹤0.01% 2109
2026
Q1 		$931K Sell
49,103
-289,287
-85% -$4.68M ﹤0.01% 2803
2025
Q4 		$5.92M Sell
338,390
-137,387
-29% -$2.58M ﹤0.01% 2083
2025
Q3 		$9.83M Buy
475,777
+161,953
+52% +$3.93M ﹤0.01% 1670
2025
Q2 		$6.68M Buy
313,824
+58,212
+23% +$1.33M ﹤0.01% 1873
2025
Q1 		$4.93M Sell
255,612
-74,534
-23% -$1.5M ﹤0.01% 1931
2024
Q4 		$5.89M Buy
330,146
+80,028
+32% +$1.55M ﹤0.01% 2001
2024
Q3 		$5.48M Sell
250,118
-137,195
-35% -$1.92M ﹤0.01% 2014
2024
Q2 		$3.02M Sell
387,313
-5,999
-2% -$32.4K ﹤0.01% 1852
2024
Q1 		$1.63M Buy
393,312
+74,747
+23% +$297K ﹤0.01% 2741
2023
Q4 		$831K Buy
318,565
+170,549
+115% +$351K ﹤0.01% 3580
2023
Q3 		$277K Buy
148,016
+99,744
+207% +$190K ﹤0.01% 3128
2023
Q2 		$121K Sell
48,272
-198,192
-80% -$362K ﹤0.01% 3493
2023
Q1 		$431K Buy
246,464
+232,605
+1,678% +$634K ﹤0.01% 3367
2022
Q4 		$58.9K Buy
13,859
+11,770
+563% +$21.4K ﹤0.01% 4488
2022
Q3 		$2K Buy
2,089
+961
+85% +$1.09K ﹤0.01% 4642
2022
Q2 		$1K Sell
1,128
-3,233
-74% -$4.53K ﹤0.01% 4952
2022
Q1 		$11K Buy
+4,361
New +$11K ﹤0.01% 4588

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Barclays's SMMT Position: Q2 2026 in Review

Barclays increased its Summit Therapeutics (SMMT) stake by 328% in Q2 2026, buying an estimated $2.86M and bringing the position to 210,207 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Barclays first reported a position in SMMT in Q1 2022 and has held it in 18 quarters since. The position peaked at $9.83M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Barclays held 210,207 shares of Summit Therapeutics worth $3.06M as of Q2 2026.
  • Barclays bought 161,104 Summit Therapeutics shares in Q2 2026, an estimated $2.86M.
  • Summit Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2109 holding.
  • Barclays first reported a position in Summit Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Summit Therapeutics position peaked at $9.83M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.